Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
About the Company : Established in 2002, Tecoland represents selected cGMP manufacturers with proven capabilities in organic synthesis, fermentation production as well as process and method developmen...
About the Company : We are a world class innovation driven specialty pharmaceutical company with integrated Research, Development, Manufacturing and Marketing of Quality affordable medicines for a Hea...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Results from the NOPHO-sponsored Phase 2 clinical trial demonstrated that eryaspase in combination with chemotherapy, administered every two weeks, provides a sustained asparaginase enzyme activity level, and is generally well tolerated with few hypersentivity reactions.
Lead Product(s): Peg L asparaginase
Therapeutic Area: Oncology Brand Name: Eryaspase
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2021
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
Details : Results from the NOPHO-sponsored Phase 2 clinical trial demonstrated that eryaspase in combination with chemotherapy, administered every two weeks, provides a sustained asparaginase enzyme activity level, and is generally well tolerated with few hypersen...
Brand Name : Eryaspase
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 20, 2021
Details:
Oral presentation to discuss findings from the Nordic Society of Paediatric Haematology and Oncology (NOPHO)-sponsored Phase 2 trial that confirm the potential of eryaspase as a treatment option for ALL.
Lead Product(s): Peg L asparaginase
Therapeutic Area: Oncology Brand Name: Eryaspase
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Oral presentation to discuss findings from the Nordic Society of Paediatric Haematology and Oncology (NOPHO)-sponsored Phase 2 trial that confirm the potential of eryaspase as a treatment option for ALL.
Brand Name : Eryaspase
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 05, 2020
Details:
Primary finding of the NOR-GRASPALL-2016 trial suggest that eryaspase achieved the target level and duration of asparaginase activity in these patients.
Lead Product(s): Peg L asparaginase
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Primary finding of the NOR-GRASPALL-2016 trial suggest that eryaspase achieved the target level and duration of asparaginase activity in these patients.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 09, 2020
Details:
TRYbeCA-1 is a randomized, controlled Phase 3 clinical trial evaluating eryaspase in second-line metastatic pancreatic cancer. The primary endpoint of TRYbeCA1 is overall survival (OS). The trial is designed to identify a OS hazard ratio (HR) of 0.72 with close to 90% power.
Lead Product(s): Peg L asparaginase,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Lead Product(s) : Peg L asparaginase,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ERYTECH Announces Poster Presentations at ASCO 2020 Annual Meeting
Details : TRYbeCA-1 is a randomized, controlled Phase 3 clinical trial evaluating eryaspase in second-line metastatic pancreatic cancer. The primary endpoint of TRYbeCA1 is overall survival (OS). The trial is designed to identify a OS hazard ratio (HR) of 0.72 wit...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 01, 2020
Details:
ERYTECH’s lead product candidate, eryaspase, is being evaluated in a Phase 3 trial (TRYbeCA-1) in second-line metastatic pancreatic cancer in 11 countries in Europe and the United States.
Lead Product(s): Peg L asparaginase,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
Lead Product(s) : Peg L asparaginase,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer
Details : ERYTECH’s lead product candidate, eryaspase, is being evaluated in a Phase 3 trial (TRYbeCA-1) in second-line metastatic pancreatic cancer in 11 countries in Europe and the United States.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 28, 2020
Details:
More than 75% of the planned ~500 patients enrolled in the trial evaluating eryaspase. Eryaspase is made of L-asparaginase placed inside donor-derived red blood cells.
Lead Product(s): Peg L asparaginase,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Lead Product(s) : Peg L asparaginase,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : More than 75% of the planned ~500 patients enrolled in the trial evaluating eryaspase. Eryaspase is made of L-asparaginase placed inside donor-derived red blood cells.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Comment (2)
